Entropy Neurodynamics Showcases TRP-8803 Platform at Australian Microcap Conference

An update from Tryptamine Therapeutics ( (AU:ENP) ) is now available.

Entropy Neurodynamics Limited has announced that its Managing Director and CEO, Jason Carroll, will present at the 15th Annual Australian Microcap Investment Conference in Sydney, highlighting the company’s proprietary TRP-8803 intravenous psilocin platform. The presentation will cover recent breakthrough clinical results in treatment-resistant irritable bowel syndrome and outline the company’s broader strategy to advance precision-controlled psychedelic therapies, reinforcing its positioning in the emerging field of gut-brain and neuropsychiatric treatments.

The company notes that development of TRP-8803 builds on Phase 2a trials using oral psilocybin in binge eating disorder, irritable bowel syndrome and fibromyalgia, which showed clinical benefit and will inform further product refinement. Entropy is also encouraging investors to register via the Automic Group portal for electronic communications, underscoring its efforts to deepen investor engagement as it progresses its clinical and commercial plans.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is a clinical-stage biotechnology company developing proprietary formulations of psilocin, the active metabolite of psilocybin, administered via intravenous infusion alongside psychotherapy. Its lead program, TRP-8803, targets diseases with unmet medical needs, aiming to improve control over onset, depth, and duration of psychedelic experiences in neuropsychiatric and gut-brain disorders.

Average Trading Volume: 2,384,171

Technical Sentiment Signal: Buy

Current Market Cap: A$59.56M

See more data about ENP stock on TipRanks’ Stock Analysis page.